deltatrials
Completed PHASE2 NCT01195415

Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer

Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Pancreatic Carcinoma Stage IV Pancreatic Cancer
Interventions Gemcitabine Hydrochloride Laboratory Biomarker Analysis Vismodegib
Updated 7 times since 2017 Last updated: Aug 2, 2017 Started: Jun 30, 2010 Primary completion: Jul 31, 2013 Completion: Oct 10, 2014

Listed as NCT01195415, this PHASE2 trial focuses on Recurrent Pancreatic Carcinoma and Stage IV Pancreatic Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

  1. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Ann Arbor, United States